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ABSTRACT 
 Atherosclerotic plaque rupture is closely related to acute coronary 
syndromes.Stabilization of atherosclerotic plaque which slashes plaque rupture is as 
importantas regression ofplaque size for reducing cardiovascular events. Dyslipidemia therapy 
targeting to decrease LDL cholesterol reduces cardiovascular events such as acute myocard 
infarct, stroke, and death which are suggested to be the result of plaque stabilization. 
Dyslipidemia therapy also regress atherosclerotic plaque into a smaller volume. Plaque 
regression improves coronary flow responsible for the reduction of myocardial infarction 
incidence in patients with coronary heart disease (CHD).This paper consists of two parts. The 
first part discusses the evidence of cardiovascular event reduction with statin. The second part 
describes dyslipidemia management based on the 2017 Indonesian Heart Association (PERKI) 
Guideline on the Management of Dyslipidemia 
 
Dyslipidemia therapy stabilizes and 
regress atherosclerotic plaque 
 Dyslipidemia therapy has two 
purposes. The first is to stabilize 
atherosclerotic plaque from being ruptured, 
thus preventing acute coronary syndromes, 
stroke, and death. The second is to reduce 
plaque volume (plaque regression). Stable 
plaque consists of less macrophage and 
oxidized LDL and has thicker fibrous cap 
despite of normal plaque volume.  
Regressed plaque has smaller volume 
without changes of the plaque component 
and thickness of the fibrous cap. 
 The JUPITER study is a study with 
the objective to see the effect of lowering 
LDL cholesterol with rosuvastatin on 
cardiovascular events i.e. myocardial 
infarction and ischemia, stroke, and 
cardiovascular death. This study was 
conducted inhigh-risk subjects without 
cardiovascular disease (CVD). Therapy with 
rosuvastatin 20 mg for 4 years has been 
shown to significantly reduce cardiovascular 
events by 44%. The therapeutic effect is 
seen several months after starting 
treatmentthat indicates the stabilization of 
atherosclerotic plaques. The results of the 
JUPITER study support statin administration 
as soon as possible for patients with high 
cardiovascular risk. 
 Another study with rosuvastatin 
(ASTEROID study) showed that rosuvatatin 
40 mg for 2 years regressed atherosclerotic 
plaques in subjects with CHD. The results of 
the ASTEROID study provide support for 
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administering high-dose statin therapy for 
CHD patients. 
Management of dyslipidemia  
 Among the lipid profiles routinely 
examined, only LDL cholesterol is 
stronglyrelated to cardiovascular events in 
randomized clinical trials. This fact 
makesLDL cholesterol to be the primary 
target of dyslipidemia management. LDL 
cholesterol must be lowered to itstarget 
level before managing other lipids. 
Triglycerides reduce cardiovascular events 
in subjects with high cardiovascular 
riskonlyifLDL cholesterol has been lowered 
to target. There is no target for 
triglycerides.However, triglycerides should 
be lowered immediatelyif the concentration 
is ≥500 mg/dl to avoid acute pancreatitis. 
The secondary target of treatment is non-
HDL cholesterol calculated by reducing the 
concentration of HDL to total cholesterol. 
 Total and HDL cholesterol although 
routinely examined are not the target of 
treatment given the lack of adequate clinical 
evidence. Total cholesterol and HDL 
cholesterol are used in cardiovascular risk 
stratification. Routine examination forother 
lipid profiles is not advisedexcept in certain 
clinical condition. 
 The management discussed here 
refers to the 2017 PERKI Dyslipidemia 
Management Guideline. The guidelines 
introduce step-by-step approach (5 steps) 
that is intended to help physician to deal 
with lipid management. 
The first step  
Screening for dyslipidemia is always 
indicated in subjects withclinical 
manifestations of CVD, in clinical conditions 
associatedwith increased risk for CVD and 
whenever risk factor screeningis 
considered. Recognition of dyslipidemia 
requires information of CVD risk level i.e. 
very high, high, moderate, and low. The cut-
off points used to definerisk level are partly 
arbitrary and based on the risk level at 
which treatment benefit is evident in clinical 
trials.   
Risk level is influenced by the 
presence of 5 clinical conditions that needs 
to be investigated,i.e.atherosclerotic 
cardiovascular diseases, diabetes mellitus 
(DM), chronic kidney disease (CKD), 
uncontrolled hypertension, and familial 
hypercholesterolemia. Atherosclerotic 
cardiovascular diseaserefers to 
atherosclerosis ofany blood vessel such as 
coronary (CHD), brain (ischemic stroke), 
and peripheral vessels (peripheral arterial 
disease). Chronic kidney disease (CKD) is 
defined asGFR of less than 60 
ml/minute/1.73 m2.  
 Patients with atherosclerotic 
cardiovascular diseases, CKD with a GFR 
of less than 30 ml/minute/1.73 m2, or DM 
with albuminuria or other risk factors are 
classified as very high risk. The high 
cardiovascular risk is proposed for those 
with DM who do not meet the very high risk 
criteria, CKD with a GFR of 30-59 
ml/minute/1.73 m2, severe hypertension 
(systolic BP exceeds 160 mm Hg) 
uncontrolled with drugs, and familial 
hypercholesterolemia (total cholesterol 
above 310 mg/dl).For all other patients, 
CVD risk is estimated using the SCORE 
chart.See the 2017 PERKI Dyslipidemia 
Management Guideline for detail of SCORE 
estimation system. The guideline can be 
downloaded for free at www.inaheart.com.   
The second step  
 The second step is defining LDL 
cholesterol treatment target based on 
patient’s risk level. A person with LDL 
cholesterol above the treatment target is 
defined as dyslipidemia,in whom LDL 
cholesterol lowering treatment should be 
initiated. The LDL cholesterol treatment 
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target for those with very high, high, or 
middle/low risk is<70 mg/dl, <100 mg/dl, 
or<115 mg/dl respectively.  
The third step  
 The third step is to develop a 
strategy to achieve the target of LDL 
cholesterol. The strategy requires 
information of a) LDL cholesterol 
concentration at baseline, b) LDL 
cholesterol target, and c) the available 
treatment choices. The strategy should 
always include therapeutic lifestyle changes 
(not discussed in this paper) with or without 
LDL cholesterol-lowering drug. Drug therapy 
is indicated for all patients with LDL 
cholesterol above treatment target, except 
for patients at low risk and myocardial 
infarction. Drug therapy for low-risk patients 
is indicated if the baseline LDL cholesterol 
is ≥190 mg/dl. Patients with acute 
myocardial infarction should receive LDL 
cholesterol-lowering therapy regardless of 
their baseline LDL cholesterol. 
 Given that proprotein convertase 
substilysin kexin9 (PCSK9) inhibitor is not 
available in Indonesia, discussion of LDL 
cholesterol lowering drug treatment refers to 
statin and its combination with ezetimibe. 
Statin/ezetimibe combinationis indicated for 
those with high and very high 
cardiovascular risk if the baseline LDL 
cholesterol is ˃200 mg/dl and >135 mg/dl 
respectively. High-dose statins cannot 
reduce such high LDL cholesterol to 
target.The combination of statin/ezetimibe is 
also indicated for those in whom LDL 
cholesteroltarget is not reached despite 
treatment with high-dose statins. 
The fourth step  
 The fourth step is the management 
of non-HDL cholesterol for patients with 
high and very high cardiovascular risk in 
whom LDL cholesterol has reached the 
target level and the non-HDL cholesterol is 
still ˃30 mg/dl above the target of LDL 
cholesterol. Thus, non-HDL cholesterol 
therapy is initiated in high and very high risk 
patients if >130 mg/dl and ˃100 mg/dl 
respectively. Use fibrate to lower non-HDL 
cholesterol. Fenofibrates is preferred over 
gemfibrozil. 
The fifth step  
 The final step is monitoring the LDL 
cholesterol, SGPT, and creatinine kinase. 
Before starting statin therapy, check the 
LDL cholesterol twice except for very high 
risk patients or those with acute coronary 
syndrome.Repeat the test after 1-12 weeks. 
Start drug treatment immediately for 
patients at very-high risk or with acute 
coronary syndrome.Repeat LDL cholesterol 
test 4-12 weeks after treatment initiation or 
dose change. If the LDL cholesterol 
concentration has reached the treatment 
target, repeat the test yearly.  
 SGPT is examined before statin 
therapy and 8-12 weeks thereafter or after 
changing the dose. If SGOT increases <3 x 
upper limit of normal (ULN), continue statin 
and repeat SGPT testing after 4-6 weeks. 
Postpone or stop statin therapy for 4-6 
weeks if SGPT is ≥3x ULN and repeat the 
test before resuming statin. Therapy can be 
resumed if SGPT has returned to normal. 
Creatinine kinase is examined if there is 
unexplained muscle pain (myalgia) that 
does not respond to pain killer. Follow the 
algorithm below if there is an increase in 
creatinine kinase. 
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CETP = cholesteryl ester transfer protein; CK = creatine kinase; LDL-C= low-density lipoprotein 
cholesterol; PCKS9 = propoteinonvertasesubtilisin/kesin type 9; ULN = upper limit of the normal range. 
aEfficacious statin such as atorvastatin or rosuvastatin 
(Catapano AL, et al. Eur Heart J 2016. doi:10.1093/eurheartj/ehw272) 
